Search results for "amine"

showing 10 items of 7299 documents

Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Me…

2019

Background Impaired subjective well-being in schizophrenia patients treated with antipsychotics has often been linked inter alia to the antidopaminergic effects of medication. Thus, it is important to capture the association between striatal dopamine D2 receptor occupancy (D2-RO) and global subjective well-being. We examined this association using data from our multicenter, randomized, double-blind Neuroleptic Strategy Study (NeSSy). Methods An innovative double randomization process was used for allocation of patients to the specific treatment groups. Plasma drug concentrations were measured after 6 and 24 weeks of treatment to obtain the estimated D2-RO (eD2-RO) relative to literature val…

AdultMaleOlanzapinemedicine.medical_specialtymedicine.medical_treatmentAripiprazolePersonal SatisfactionMedication Adherencelaw.invention03 medical and health sciencesSex Factors0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHaloperidolHumansPharmacology (medical)AntipsychoticReceptors Dopamine D2business.industryMiddle Agedmedicine.disease3. Good health030227 psychiatryFlupentixolFlupenthixolDopamine D2 Receptor AntagonistsPsychiatry and Mental healthOlanzapineSchizophreniaQuality of LifeSchizophreniaHaloperidolQuetiapineFemaleSchizophrenic PsychologyAripiprazolebusiness030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Association of functional DBH genetic variants with alcohol dependence risk and related depression and suicide attempt phenotypes: Results from a lar…

2012

Abstract Objective Dopamine-beta-hydroxylase (DBH) metabolizes the conversion of dopamine to noradrenaline. DBH, located on chromosome 9q34.2 has variants with potential functional consequences which may be related to alterations of neurotransmitter function and several psychiatric phenotypes, including alcohol dependence (AD), depression (MD) and suicidal behavior (SA). The aim of this association study in a large multicenter sample of alcohol-dependent individuals and controls is to investigate the role of DBH SNPs and haplotypes in AD risk and associated phenotypes (AD with MD or SA). Method 1606 inpatient subjects with DSM-IV AD from four addiction treatment centers and 1866 control sub…

AdultMaleOncologymedicine.medical_specialtyGenotypePoison controlSuicide AttemptedSingle-nucleotide polymorphismDopamine beta-HydroxylaseToxicologyPolymorphism Single NucleotideRisk AssessmentLinkage DisequilibriumGermanyInternal medicinemedicineHumansSNPPharmacology (medical)Age of OnsetDepression (differential diagnoses)PharmacologyDepressive DisorderSex CharacteristicsSuicide attemptAlcohol dependenceHaplotypeDNAMiddle AgedAlcoholismPsychiatry and Mental healthPhenotypeCase-Control StudiesSample SizeEtiologyFemalePsychologyGenome-Wide Association StudyClinical psychologyDrug and Alcohol Dependence
researchProduct

TheMAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression

2006

This study investigated the possible association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized double-blind controlled clinical trial. Female mirtazapine-treated patients homozygous for the T-allele had a significantly faster and better treatment response than TG/GG-patients. In males, we failed to show an association between MAOA T941G gene variant and mirtazapine response. In the paroxetine-treated group, there were no significant differences in treatment response between MAOA T941G genotype groups. Time course of response and antidepressant eff…

AdultMaleOncologymedicine.medical_specialtyTime FactorsGenotypeGenetic LinkageMirtazapineMirtazapineMianserinPolymorphism Single NucleotideCellular and Molecular NeuroscienceDouble-Blind MethodGene FrequencyInternal medicineGenotypemedicineHumansAlleleMonoamine OxidaseGenotypingGenetics (clinical)Depressive Disorder MajorSex Characteristicsbusiness.industryMiddle AgedParoxetineAntidepressive AgentsClinical trialParoxetinePsychiatry and Mental healthTreatment OutcomeEndocrinologyAntidepressantFemalebusinessReuptake inhibitormedicine.drugAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics
researchProduct

Effects of the NMDA-receptor antagonist ketamine on perceptual correlates of long-term potentiation within the nociceptive system

2007

We recently reported perceptual correlates of long-term potentiation (LTP) of synaptic strength within the nociceptive system demonstrating the functional relevance of LTP for human pain sensation. LTP is generally classified as NMDA-receptor dependent or independent. Here we show that low doses of the NMDA-receptor antagonist ketamine (0.25 mg/kg) prevented the long-term increase in perceived pain to electrical test stimuli, which was induced by high-frequency electrical stimulation (HFS) of nociceptive afferents. Whereas in a control experiment HFS led to a stable increase in perceived pain by 51% for the entire observation period of 1 h HFS given 4 min after i.v. ketamine was ineffective…

AdultMalePain ThresholdLong-Term PotentiationStimulationCellular and Molecular NeurosciencePhysical StimulationReaction TimemedicineHumansKetaminePain MeasurementPharmacologyAnalysis of VarianceCross-Over Studiesintegumentary systemDose-Response Relationship RadiationLong-term potentiationNociceptionAllodyniaHyperalgesiaNeuropathic painHyperalgesiaNMDA receptorFemaleKetaminemedicine.symptomPsychologyExcitatory Amino Acid AntagonistsNeurosciencemedicine.drugNeuropharmacology
researchProduct

Zolmitriptan inhibits neurogenic inflammation and pain during electrical stimulation in human skin.

2014

Background Triptans are agonists to 5-HT 1B/D/F receptors, which are present on nociceptive neurons not only within but also beyond the trigeminal system. The aim of this study was to investigate whether zolmitriptan interacts with peptidergic nociceptive afferents in human skin. Methods Twenty participants (13 women, median age: 25; interquartile range: 23–26 years) entered the randomized, double-blind, cross-over study. Electrically induced neurogenic flare and pain was assessed after either placebo or zolmitriptan on the ventral thigh. Mechanical pain thresholds were investigated at baseline and after electrical stimulation at the stimulation site. Results The size of the neurogenic flar…

AdultMalePain ThresholdMigraine DisordersPainStimulationZolmitriptanHuman skinTriptansPharmacologyPlaceboYoung AdultDouble-Blind MethodPhysical StimulationmedicineHumansNeurons AfferentOxazolidinonesPain MeasurementSkinNeurogenic inflammationCross-Over Studiesbusiness.industryNociceptorsElectric StimulationTryptaminesSerotonin Receptor AgonistsAnesthesiology and Pain MedicineNociceptionAnesthesiaHyperalgesiaFemalemedicine.symptomNeurogenic Inflammationbusinessmedicine.drugEuropean journal of pain (London, England)
researchProduct

The use of ketamine in a palliative-supportive care unit: a retrospective analysis.

2018

Background: To assess the response to ketamine in patients with difficult pain syndromes. Methods: The charts of patients with uncontrolled pain despite opioid dose escalation of at least two opioids or a combination of them, selected for a burst of ketamine and midazolam were reviewed. One hundred mg/day of ketamine and midazolam 15 mg/day by a continuous intravenous infusion for about 48 hours was offered to patients. Results: Forty-four patients received a burst of ketamine. Ten patients did not achieve any improvement. Pain intensity decreased from a mean of 7.8 (SD, 1.6) to 2.8 (SD, 1.3) (P<0.0005). The outcome was considered optimal, good, and mild in 24, 9, and 1 patients, respective…

AdultMalePalliative careMidazolamAdverse effect03 medical and health sciences0302 clinical medicineRetrospective analysisMedicineHumansPain ManagementKetamine030212 general & internal medicineAdverse effectRefractory painAgedRetrospective StudiesAdvanced and Specialized NursingAged 80 and overbusiness.industryPalliative CareRetrospective cohort studyCancer PainMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineOpioidChemotherapy AdjuvantAnesthesiaMidazolamFemaleKetaminebusinessCancer pain030217 neurology & neurosurgerymedicine.drugAnnals of palliative medicine
researchProduct

Functional, biochemical and morphological studies on human bronchi after cryopreservation

1995

1. Human isolated bronchi have been investigated as fresh tissue or after storage (7 and 30 days) at -196 degrees C in foetal calf serum containing 1.8 M dimethyl sulphoxide. 2. After cryopreservation, the maximal contractile response to acetylcholine (3 mM) was reduced (approximately 25%) but the difference did not reach significance statistically. Maximal responses to other spasmogens tested (histamine, [Nle10]NKA(4-10), bradykinin, leukotriene D4, U46619, and KCl) did not differ between unfrozen and frozen/thawed tissues. The sensitivity of cryopreserved tissues to the constrictor agents tested was similar to that of fresh tissues. 3. The accumulation of inositol phosphates produced by a…

AdultMalePathologymedicine.medical_specialtyLung NeoplasmsInositol PhosphatesBronchiIn Vitro TechniquesBiologyTritiumCryopreservationAndrologychemistry.chemical_compoundFresh TissueIsoprenalinemedicineHumansDimethyl SulfoxideRolipramAgedCryopreservationPharmacologyMicroscopyMiddle AgedAcetylcholinechemistryFemaleSodium nitroprussidemedicine.symptomAcetylcholineHistamineMuscle ContractionResearch Articlemedicine.drugMuscle contractionBritish Journal of Pharmacology
researchProduct

Avoidance behaviour: A predictor of the efficacy of pharmacotherapy in panic disorder?

1991

The impact of the avoidance behaviour on the psychopharmacological treatment of panic disorder was explored in the Cross National Collaborative Panic Study (n = 1134 patients); in this double blind randomized trial alprazolam, imipramine and placebo were compared during an 8-week treatment period. Patients with extensive avoidance behaviour (agoraphobia) had the most profit from the active drugs. Counter expectancy these specific drug effects were most pronounced in avoidance behaviour. Active drugs (in particular imipramine) were especially more effective than placebo if the patients presented with associated avoidance behaviour. The results suggest that agoraphobia defines more a particul…

AdultMalePersonality TestsImipraminemedicine.medical_specialtyPlacebobehavioral disciplines and activitiesImipraminelaw.inventionDouble-Blind MethodRandomized controlled triallawmental disordersmedicineHumansPharmacology (medical)Social BehaviorPsychiatryAgoraphobiaBiological PsychiatryAlprazolamPanic disorderPanicFearGeneral Medicinemedicine.diseasePanichumanitiesPsychiatry and Mental healthAlprazolamPanic DisorderFemalemedicine.symptomArousalPsychologyAnxiety disordermedicine.drugAgoraphobiaClinical psychologyEuropean Archives of Psychiatry and Clinical Neuroscience
researchProduct

Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross-National Collaborati…

1991

The relevance of the chronology between panic disorder and avoidance behavior and of an early, medium or late onset of panic disorder was tested. Groups from the sample of the cross-national collaborative panic study (CNCPS) were compared for differences in basic characteristics and for the ability to predict treatment response. Patients who developed avoidance behavior before the full syndrome of panic disorder had less often a full agoraphobia but were not different in their response to treatment. Patients with an early onset of panic disorder suffered more often from agoraphobia. The treatment response was similar in the groups with early, medium or late onset of panic disorder. Neither …

AdultMalePersonality Testsmedicine.medical_specialtyImipramineLate onsetbehavioral disciplines and activitiesImipramineDrug Administration Schedulelaw.inventionRandomized controlled triallawmental disordersmedicineHumansPharmacology (medical)PsychiatryBiological PsychiatryAlprazolamGeneral NeurosciencePanic disorderAge FactorsPanicGeneral MedicineMiddle Agedmedicine.diseasePrognosisAnxiety DisordersPanichumanitiesPsychiatry and Mental healthNeuropsychology and Physiological PsychologyAlprazolamFemalemedicine.symptomAge of onsetPsychologyArousalmedicine.drugClinical psychologyAgoraphobiaEuropean archives of psychiatry and clinical neuroscience
researchProduct

Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine

1977

The effect of cholestyramine (12 gm/day divided into 3 doses) on the pharmacokinetics and pharmacodynamics of a single intravenouse dose (30 mg) of phenprocoumon was studied in 6 normal subjects. Cholestyramine treatment led to an increase in the rate of elimination of phenprocoumon in all. Total clearance increased 1.5- to 2-fold. The total anticoagulant effect per dose was considerably reduced during treatment with cholestyramine. Binding studies in vitro showed that phenprocoumon is strongly bound to cholestyramine and that at a given cholestyramine concentration the percentage of phenprocoumon bound remained constant over a large concentration range of phenprocoumon. The results suggest…

AdultMalePharmacologyCholestyramineAnticoagulant effectDose-Response Relationship DrugChemistryCholestyramine Resin4-HydroxycoumarinsMiddle AgedPharmacologyPhenprocoumonLiverPharmacokineticsEnterohepatic CirculationPhenprocoumonmedicineHumansPharmacology (medical)Enterohepatic circulationHalf-Lifemedicine.drugClinical Pharmacology &amp; Therapeutics
researchProduct